Table II.
Effects of Renin‐Angiotensin System (RAS)‐Blocking Regimens vs. Non‐RAS‐Blocking Regimens on CV End Points
| HOPE 12 | ALLHAT 14 | LIFE 5 | VALUE 15 | ASCOT 16 | |
|---|---|---|---|---|---|
| No. of patients | 9297 | 33,357 | 9193 | 15,245 | 19,342 |
| Age (yr) | 66 | 67 | 67 | 67 | 63 |
| CAD (%) | 80 | 25 | 16 | 45 | 17 |
| Diabetes (%) | 39 | 36 | 13 | 33 | 22 |
| BP advantage (regimen) | RAS | Non‐RAS | RAS | Non‐RAS | RAS |
| SBP difference (mm Hg) | ABPM, −10; office, −3 | −2 to −3 | −1.3 | −2 to −4 | −2.9 |
| CV end points difference (%) | −22 | ND | −13 | ND | −24 |
| Trial acronyms are expanded in text. CV=cardiovascular; CAD=coronary artery disease; BP=blood pressure; SBP=systolic BP; ABPM=ambulatory BP monitoring; ND=no difference | |||||